ATE416754T1 - Mukoadhäsive zusammensetzung mit polyacrylat und einem chemolockstoff - Google Patents

Mukoadhäsive zusammensetzung mit polyacrylat und einem chemolockstoff

Info

Publication number
ATE416754T1
ATE416754T1 AT04740892T AT04740892T ATE416754T1 AT E416754 T1 ATE416754 T1 AT E416754T1 AT 04740892 T AT04740892 T AT 04740892T AT 04740892 T AT04740892 T AT 04740892T AT E416754 T1 ATE416754 T1 AT E416754T1
Authority
AT
Austria
Prior art keywords
chemolockist
polyacrylate
mucoadhesive composition
composition
mucoadhesive
Prior art date
Application number
AT04740892T
Other languages
English (en)
Inventor
Pascale Hubert
Brigitte Evrard
Luc Delattre
Jacques Boniver
Philippe Delvenne
Agnes Noel
Francis Frankenne
Jean-Michel Foidart
Original Assignee
Univ Liege
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Liege filed Critical Univ Liege
Application granted granted Critical
Publication of ATE416754T1 publication Critical patent/ATE416754T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT04740892T 2003-07-31 2004-07-09 Mukoadhäsive zusammensetzung mit polyacrylat und einem chemolockstoff ATE416754T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0317999.1A GB0317999D0 (en) 2003-07-31 2003-07-31 Improvements in or relating to drug delivery systems

Publications (1)

Publication Number Publication Date
ATE416754T1 true ATE416754T1 (de) 2008-12-15

Family

ID=27799593

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04740892T ATE416754T1 (de) 2003-07-31 2004-07-09 Mukoadhäsive zusammensetzung mit polyacrylat und einem chemolockstoff

Country Status (8)

Country Link
US (1) US20060228417A1 (de)
EP (1) EP1658046B1 (de)
JP (1) JP2007500673A (de)
AT (1) ATE416754T1 (de)
AU (1) AU2004262873A1 (de)
DE (1) DE602004018326D1 (de)
GB (1) GB0317999D0 (de)
WO (1) WO2005013933A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1674077A1 (de) * 2004-12-27 2006-06-28 Université de Liège Mucoadhasive Formulierungen enthaltend Chemokine
WO2006084131A2 (en) * 2005-02-01 2006-08-10 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Furin inhibitors and alpha-defensins for the treatment or prevention of papillomavirus infection
US7528107B2 (en) 2005-11-30 2009-05-05 Auburn University Methods of treating inflammation in mammalian tissues comprising administering human alpha-defensins
WO2007065128A2 (en) * 2005-11-30 2007-06-07 Auburn University Human alpha-defensins inhibit interleukin-1beta release
DK2347775T3 (da) 2005-12-13 2020-07-13 Harvard College Skabeloner til celletransplantation
US9770535B2 (en) 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
CN102006891B (zh) 2008-02-13 2017-04-26 哈佛学院董事会 连续的细胞程序化装置
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
WO2010060104A2 (en) 2008-11-24 2010-05-27 Moma Therapeutics Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone praticles as scaffolds for tissue regeneration
US8728456B2 (en) 2009-07-31 2014-05-20 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
EP3620185A1 (de) 2010-10-06 2020-03-11 President and Fellows of Harvard College Injizierbare porenbildende hydrogele für materialbasierte zelltherapien
ES2685327T3 (es) 2011-04-28 2018-10-08 President And Fellows Of Harvard College Armazones tridimensionales macroscópicos preformados inyectables para administración mínimamente invasiva
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
AU2012261848B2 (en) 2011-06-03 2017-06-15 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
PT2838515T (pt) 2012-04-16 2020-02-25 Harvard College Composições de sílica mesoporosa para modular respostas imunológicas
CA2890757C (en) 2012-11-14 2021-10-26 Smith & Nephew, Inc. Stable thermolysin hydrogel
RU2015137174A (ru) 2013-03-15 2017-04-24 Смит энд Невью, Инк. Растворимая образующая гель плёнка и способ очистки раны
EP3137105A4 (de) 2014-04-30 2017-12-27 President and Fellows of Harvard College Kombinationsimpfstoffvorrichtungen und -verfahren zur abtötung von krebszellen
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
CN114099793A (zh) 2015-04-10 2022-03-01 哈佛学院院长等 免疫细胞捕获装置及其制备和使用方法
CN115487351A (zh) 2016-02-06 2022-12-20 哈佛学院校长同事会 重塑造血巢以重建免疫
TW201808987A (zh) * 2016-06-08 2018-03-16 健生生物科技公司 Ｇｍ－ｃｓｆ變體及使用方法
EP3484448B1 (de) 2016-07-13 2025-04-09 President and Fellows of Harvard College Antigenpräsentierende zellmimetische gerüste und verfahren zur herstellung und verwendung davon
RU2770060C2 (ru) 2016-08-02 2022-04-14 Президент Энд Феллоуз Оф Гарвард Колледж Биологические материалы для модуляции иммунных ответов
WO2020002650A1 (en) * 2018-06-29 2020-01-02 Targovax Asa A formulation
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
EP4034148A4 (de) 2019-09-23 2025-09-10 Harvard College Biomaterialbasierter antigenfreier impfstoff und verwendung davon

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
ATE442844T1 (de) * 1996-11-14 2009-10-15 Lipomedica Ehf Topische zusammensetzungen enthaltend als therapeutisch aktiven wirkstoff ein monoglycerid zur behandlung von schleimhautinfektionen
US6355270B1 (en) * 1999-01-11 2002-03-12 The Regents Of The University Of California Particles for oral delivery of peptides and proteins
US7544348B2 (en) * 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders

Also Published As

Publication number Publication date
US20060228417A1 (en) 2006-10-12
AU2004262873A1 (en) 2005-02-17
JP2007500673A (ja) 2007-01-18
WO2005013933A1 (en) 2005-02-17
DE602004018326D1 (de) 2009-01-22
GB0317999D0 (en) 2003-09-03
EP1658046B1 (de) 2008-12-10
EP1658046A1 (de) 2006-05-24

Similar Documents

Publication Publication Date Title
DE602004018326D1 (de) Mukoadhäsive zusammensetzung mit polyacrylat und einem chemolockstoff
BRPI0312331A2 (pt) composições de ácido hialurônico e métodos de emprego.
EP1476403A4 (de) Aerobes biomassengranulat für die abwasserbehandlung
NO20030885L (no) Inhibitorer av <alfa>4 styrt celleadhesjon
EP1957413A4 (de) Abwasserbehandlung
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
PT1235799E (pt) Forma polimorfica de atorvastatina-calcio
EA200500453A1 (ru) Имидазопиридины и способы их получения и применения
DE60106229D1 (de) Uv-verstärktes silylierungsverfahren zur erhöhung des ätzwiderstands von dünnen resistschichten
PL373333A1 (pl) Stosowanie przeciwciał skierowanych przeciw TNFalfa i innego leku
DE50004965D1 (de) Inhibitorkomposition zur Stabilisierung von radikalisch polymerisierbaren Substanzen
FR2834890B1 (fr) Composition pharmaceutique orodispersible d'agomelatine
EP1506786A4 (de) Medizinische, ghrelin enthaltende zusammensetzungen
DE602004019548D1 (de) Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri)
FI20040668L (fi) Platinaryhmän metalleja sisältävien malmimateriaalien valmistus
ATE494904T1 (de) Verbindungen und verfahren zur erhöhung der neurogenese
CO5690533A2 (es) Composicion farmaceutica que comprende micro-particulas de octreotida
EP1663255A4 (de) Withanamid und withanolid-zusammensetzungen und anwendungsverfahren dafür
MXPA04006266A (es) Pirimidotriazinas como inhibidores de fosfatasa.
AP1795A (en) Peptide deformylase inhibitors.
EP1624880A4 (de) Annatto-extrakt-zusammensetzungen mit geranyl-geraniolen und anwendungsverfahren
IS6654A (is) Stöðugt gabapentín með pH innan stýrðra marka
EP1695956A4 (de) Cyclische carbonsäureverbindung und deren anwendung
FR2834896B1 (fr) Composition pharmaceutique orodispersible d'ivabradine
WO2003069305A3 (en) Fluorescent phospholipase assay, phospholipase a2 inhibitor and stimulator, and the use thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties